Delcath Systems opened higher at $21.79, compared with its previous close of $21.77. In the last trading session, the stock traded between $21.14 and $22.51. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Delcath Systems is now worth
$ 197.64
Giving a profit of
$ 97.64 (97.64%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.40 (-1.81%)
Day High
$22.51
Day Low
$21.14
Day Open
$21.79
Prev Close
$21.77
Volume
9,77,574
1W Return
44.23%
1M Return
36.19%
3M Return
24.04%
6M Return
93.26%
1Y Return
147.97%
Fundamentals
Market Cap ($ Mn)
744
PE Ratio
1,635.00
PB Ratio
4.67
PEG Ratio
-
ROE
2.81%
ROCE
0.60%
EPS (TTM)
$0.20
Investment Returns
1 Week
44.23%
1 Month
36.19%
3 Months
24.04%
6 Months
93.26%
9 Months
125.00%
Financials
Quarterly
All values in $ Mn
24.2
Jun 25
20.6
Sep 25
20.7
Dec 25
25.0
Mar 26
29.1
Jun 26
35.1
Sep 26
Updates
9Nov
BTIG raises Delcath Systems price target to $25, maintains Buy rating
BTIG maintains a Buy rating on Delcath Systems. Price target raised from $21 to $25. Analyst Marie Thibault authored the update.
3 days ago
9Nov
Delcath Systems Q3 Results: EPS $0.17 beats estimate, revenue up 70.7%
EPS of $0.17 beat the analyst consensus estimate of $(0.09). Quarterly revenue rose 70.70% YoY to $35.102 million. Sales exceeded consensus estimates by 34.87%. Earnings grew 750% compared to $0.02 in the prior year period.
3 days ago
20Oct
Delcath Systems presents clinical updates at ESMO Congress 2026
Delcath Systems presented clinical development program updates at ESMO Congress 2026. Independent analysis showed 66.7% objective response rate for CS-PHP in uveal melanoma. Median overall survival reached 28 months in the 12-patient retrospective cohort. BAP1 loss and monosomy 3 identified as markers associated with shorter survival.
24 days ago
6Oct
Delcath Systems Q2FY26 Results: Revenue up 20% to $29.1 million
Total revenue rose 20% YoY to $29.1 million in Q2FY26. Hepzato Kit revenue increased 21% to $27.2 million on 30% volume growth. Full-year FY26 revenue guidance raised to $104-108 million. Gross margin expanded to 90% from 86% in the prior-year quarter. Active treatment centers increased to 31 with a target of 37 by year-end.
1mo ago
12Sep
Delcath Systems grants 34,000 RSUs to four new hires
Delcath Systems granted 34,000 RSUs to four new employees. Awards issued on September 1, 2026, under Nasdaq Rule 5635(c)(4). One-third vests after one year; remainder vests annually over two years. Grants approved by Compensation Committee as material inducements.
2mo ago
1Sep
Delcath Systems to present at Wells Fargo and Wainwright conferences in September
Management to attend Wells Fargo Healthcare Conference on September 10, 2026. Company will also speak at H.C. Wainwright conference on September 15, 2026. Delcath focuses on liver cancer treatments using HEPZATO KIT and CHEMOSAT. US approval covers metastatic uveal melanoma with limited hepatic involvement.
